Identification and Management of Vascular Risk: Beyond Low Density Lipoprotein Cholesterol

American Heart Association. (2003). Heart disease and stroke statistics 2003. Retrieved May 8, 2003, from http://americanheart.org

Assmann G. , Schulte H. , von Erardstein A. , & Huang Y. (1996). High density lipoprotein cholesterol as a predictor of cardiovascular risk: The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atheroschlerosi, 124(Suppl.), S11–S20.

Austin M.A. , McKnight B. , Edwards K. , Bradley C.M. , McNeely M. , Psaty B.M. , Brunzell J.D. , & Motulsky A.G. (2000). Cardiovascular disease mortality in familial forms of hypertriglyceridemia: A 20-year prospective study. Circulation, 101(24), 2777–2782.

Bersot T.P. (2000). Strategies for raising HDL cholesterol levels. Patient Care, 34(1), 151–157.

Boushey C.J. , Beresford S.A. , Omenn G.S. , & Motulsky A.G. (1995). A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 274(13), 1049–1057.

Brown G. , Xue-Qiao A. , Chait A. , Fisher L. , Cheung M. , Morse J. , Dowdy A. , Marino E. , Bolson E. , Alaupovic P. , Frohlich J. , Serafini L. , Huss Frechette E. , Wand S. , DeAngelis D. , Dodek A. , & Albers J. (2001). Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. New England Journal of Medicine, 345, 1583–1592.

Castelli W.P. (1984). Cholesterol and lipids in the risk of coronary disease: The Framingham Study. American Journal of Medicine, 76, 4–12.

Castelli W.P. (1992). The Framingham Study. American Journal of Cardiology, 70, 3H–9H.

Cohn P. (2003). Coffee, tea, or CRP? The Clinical Advisor, 6(2), 10–15.

Davidson M.H. (2002). The mobile lipid clinic: A companion guide. Philadelphia, PA: Lippincott Williams & Wilkins.

Downs J.M. , Clearfield M. , Weis S. , Whitney E. , Shapiro D.R. , Beere P.A. , Langendorfer A. , Stein E.A. , Kruyer W. , & Gotto A. (1998). Prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Journal of the American Medical Association, 279, 1615–1622.

Eikelboom J. , Lonti E. , Genest J. , Hankey G. , & Yusuf S. (1999). Homocysteine and cardiovascular disease: A critical review of the epidemiologic evidence. Annals of Internal Medicine, 131, 363–375.

Gagne C. , Gaudet D. , & Bruckert E. (2002). Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in clients with homozygous familial hypercholesterolemia. Circulation, 105, 2469–2475.

Gould L. , Rossouw J. , Santanello N. , Heyse J. , & Furberg C. (1995). Cholesterol reduction yields clinical benefit. Circulation, 91, 2274–2282.

Grundy S. (2001). United States cholesterol guidelines 2001: Expanded scope of intensive low-density lipoprotein-lowering therapy. American Journal of Cardiology, 88(7B), 23J–27J.

Harris W.S. , Silveria S. , & Dujoune C.A. (1990). The combined effects of N-3 fatty acid and ASA on hemostatic parameters in man. Thrombosis Research, 57, 517–526.

Heart Protection Study Collaborative Group. (2002). MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 50,536 high-risk individuals: A randomized placebo-controlled trial. Lancet, 360, 7–22.

Herbert P.R. , Gaziano K.S. , Chan K.S. , & Hennekens C.H. (1997). Cholesterol lowering with statin drugs, risk of stroke, and total mortality: An overview of randomized trails. Journal of the American Medical Association, 278, 313.

Hoerger T.J. , Bala M.V. , Bray J.W. , Wilcosky T.C. , & LaRosa J. (1998). Treatment patterns and distribution of low-density lipoprotein, cholesterol levels in treatment-eligible US adults. American Journal of Cardiology, 82, 61–65.

Jacobson T.A. , Griffiths G.G. , Varas C. , Gause D. , Sung J.C.Y. , & Ballantyne C.M. (2000). Impact of evidence based clinical judgment on the number of American adults requiring lipid-lowering therapy based on NHANES III data. National Health and Nutrition Examination Survey. Archives of Internal Medicine, 160(9), 1361–1369.

Jairath N. (1999). Coronary heart disease and risk factor management: A nursing perspective. Philadelphia, PA: W.B. Saunders.

Kennon S. , Price C.P. , Mills P.G. , Ranjadayalan K. , Cooper J. , Clarke H. , & Timmis A.D. (2001). The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. Journal of the American College of Cardiology, 37, 1266–1270.

Knopp R.H. (1999). Drug therapy: Drug treatment of lipid disorders. New England Journal of Medicine, 341, 498–511.

Kong D. , Blazing M. , & O'Connor C. (2000). Advances in approach to acute coronary syndromes. Hospital Practice, 84, 54–61.

Kris-Etherton P. , Harris W. , & Appel L. (2002). Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation, 106(21), 2747.

Kullo I.J. , Gau G.T. , & Tajik A.J. (2000). Novel risk factors for atherosclerosis. Mayo Clinic Proceedings, 75(4), 369–380.

Lenfant C. (1996). Task force on research in epidemiology and prevention of cardiovascular diseases: A revisit NHLBI cholesterol awareness surveys. Circulation, 93, 1605–1607.

Levenson J. , Giral P. , Razavian M. , Gariepy J. , & Simon A. (1995). Fibrinogen and silent atherosclerosis with cardiovascular risk factors. Arteriosclerosis Thrombosis, Vascular Biology, 15, 1263–1268.

Levine G.N. , Keaney J.F. Jr. , & Vita J.A. (1995). Cholesterol reduction in cardiovascular disease: Clinical benefits and possible mechanisms. New England Journal of Medicine, 32(8), 512–521.

Libby P. (2001). What have we learned about the biology of atherosclerosis? The role of inflammation. American Journal of Cardiology, 88(7B), 3J–6J.

Lipids Research Clinics Program. (1994). The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association, 251, 351–364.

LIPID Study Group. (1998). The lipid research in coronary primary prevention trial. New England Journal of Medicine, 339, 1349–1357.

Ma J. , Hennekens C. , Ridker P. , & Stampfer M. (1999). A prospective study of fibrinogen and risk of myocardial infarction in the physicians' health study. Journal of the American College of Cardiology, 33(5), 1347–1352.

McKenny J. , & Hawkins D. (2001). Handbook on the management of lipid disorders (2nd ed.). St. Louis, MO: National Pharmacy Cardiovascular Council.

Miller M. (1998). Lecture notes. Philadelphia, PA: Lipid Disorder Mini-Fellowship.

National Cholesterol Education Program Adult Treatment Plan III. (2001). Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Plan III). Retrieved July 14, 2003, from www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm

Olson K. , Bungard T. , & Tsuyuki R. (2001). Cholesterol risk management: A systematic examination of the gap from evidence to practice. Pharmacotherapy, 21, 807–817.

Pearson T.A. , Laurora I. , Chu H. , & Kafonek S. (2000). The lipid treatment assessment project (L-tap): A multicenter survey to evaluate the percentages of dyslipidemic clients receiving lipid-lowering therapy and achieving low-density lipodensity lipoprotein cholesterol goals. Archives of Internal Medicine, 160, 459–467.

Physicians' Health Study Research Group. (1989). Final report on the aspirin component of the ongoing Physicians' Health Study. New England Journal of Medicine, 321, 129–135.

Rader D.J. (1998). Lipid disorders. In Topol E.J. (Ed.), Textbook of cardiovascular medicine (1st ed., pp. 59–90). Philadelphia, PA: Lippincott-Raven Publishers.

Rader D. (2000a). Disorders of lipid metabolism. In Humer H.D. (Ed.). Kelly's textbook of internal medicine (4th ed., pp. 72–93). Philadelphia, PA: Lippincott Williams & Wilkins.

Rader D. (2000b). Hypercholesterolemia and other abnormal lipid profiles. In Humer H.D. (Ed.). Kelly's textbook of internal medicine (4th ed., pp. 201–214). Philadelphia, PA: Lippincott Williams & Wilkins.

Rader D. (2002). Significance of HDL cholesterol as a cardiovascular risk factor. Paper presented at the Geisinger Health System Cardiovascular Symposium, Wilkes-Barre, PA.

Rader D. , & Brewer H.B. (1992). Lipoprotein (a): Clinical approach to a unique atherogenic lipoprotein. Journal of the American Medical Association, 4, 133.

Ridker P. , Meir J. , Stampfer M. , & Rifai N. (2001). Novel risk factors for systemic atherosclerosis: A comparison of C-Reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. Journal of the American Medical Association, 285, 2481–2485.

Ridker P. , Rifai N. , Rose I. , Burnings L. , & Cook N.R. (2002). Comparison of C-reactive protein an low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine, 347, 1557.

Roberts W.C. (1996). The underused miracle drugs: The statin drugs are to atherosclerosis what penicillin was to infectious disease. American Journal of Cardiology, 78, 377–378.

Rogers B. (2003). Occupational health nursing: Concepts and practice. Philadelphia, PA: W.B. Saunders.

Rubins H.B. , Robines S.J. , Collines D. , Fye C.A. , Anderson J.W. , Elam M.B. , Faas F.H. , Linares E. , Schaefer E.J. , Schectman G. , Wilt T. , & Wittes J. (1999). Gemifibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. New England Journal of Medicine, 341, 410–418.

Sacks F.M. , Pfeffer M.A. , Moye L.A. , Rouleau J.L. , Rutherford J.D. , Cole T.G. , Brown L. , Warnica J.W. , Arnold J.M.O. , Wun C.C. , Davis B.R. , & Braunwald E. (1996). The effects of pravastatin on coronary events after myocardial infarction in clients with average cholesterol levels. New England Journal of Medicine, 335, 1001–1009.

Salazar M. (2001). AAOHN core curriculum for occupational health nursing. Philadelphia, PA: W.B. Saunders.

Scandinavian Simvastatin Survival Study (4S) Group. (1994). Randomized trial of cholesterol lowering in 4444 clients with coronary heart disease. Lancet, 44, 1383–1389.

Stefanick M.L. , Mackey S. , Sheehan M. , Elizworth N. , Haskel W. , & Wood P. (1998). Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol. New England Journal of Medicine, 339, 12–20.

Stoney C. (2000a). Plasma homocysteine levels increase in women during psychological stress: Stress increases blood chemical related to heart disease. Life Science, 66(23), 2359–2365.

Stoney C. , & Engebretson T. (2000b). Plasma homocysteine concentrations are positively associated with hostility and anger. Life Science, 66(23), 2267–2275.

Superko H.R. (1995). New aspects of CV risk factors. Current Opinions in Cardiology, 10, 347–354.

Superko H.R. (1996). Beyond LDL reduction. Circulation, 94, 2351–2354.

Szapary P. , Hart L. , & Burke F. (2002). The metabolic syndrome: A new focus for lifestyle modification. Patient Care, 36(11), 8.

Szapary P. , & Rader D. (2001). Elevated triglycerides and low HDL cholesterol. Current Opinion in Pharmacology, 1, 113–120.

Third National Health and Nutrition Examination Survey (NHANES III). (2000). Multiple risk factors. Atlanta, GA: National Center for Health Statistics.

Vasan R.S. , Beiser A. , D'Agostino R.B. , Levy D. , Selhub J. , Jacques P.F. , Rosenberg I.H. , & Wilson P.W.F. (2003). Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA, 289(10), 1251–1257.

Welch G. , & Loscalzo J. (1998). Homocysteine and atherotherombosis. New England Journal of Medicine, 338(15), 1042–1050.

West of Scotland Coronary Prevention Group. (1998). Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation, 97, 1440–1445.

Wilson P.F. , Kannel W.B. , Silbershatz H. , & D'Agostino R.B. (1999). Clustering of metabolic factors and coronary heart disease. Archives of Internal Medicine, 10(159), 1104–1109.

Wolfe M. , Vartanian S. , Ross J. , Bansavich L. , Mohler E. , Meagher E. , Friedrich C. , & Rader D. (2001). Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. American Journal of Cardiology, 87, 476–479.

Writing Group for the Women's Health Initiative. (2002). Risk and benefits of estrogen plus progestin in healthy postmenopausal women: Principle results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association, 288, 321–333.